EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access · CC BY 4.0

Efficacy and safety of [161Tb]Tb-PSMA radioligand therapy in metastatic castration resistant prostate cancer: a systematic review and meta-analysis

Domenico Albano, Gaetano Paone, Giorgio Treglia

Frontiers in Medicine · 05.08.2026 · 13

DOI: 10.3389/fmed.2026.1925657 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Frontiers in Medicine, online erschienen am 05.08.2026. Verfasst von Domenico Albano und 2 weiteren Autor:innen. Beteiligte Einrichtung: Nuclear Medicine, University of Brescia, Brescia, Italy. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) using Terbium-161 [ 161 Tb]-labeled compounds has recently been investigated in patients with metastatic castration-resistant prostate cancer (mCRPC). We performed a systematic review and meta-analysis to evaluate the efficacy and safety of [ 161 Tb]Tb-PSMA RLT in this clinical setting.

Methods

We conducted a comprehensive literature search across PubMed/MEDLINE, Embase, and the Cochrane databases to retrieve published articles on the efficacy and safety of [ 161 Tb]Tb-PSMA RLT in mCRPC. Studies reporting the use of [ 161 Tb]Tb-PSMA RLT in mCRPC patients were eligible for inclusion. Pooled estimates of disease control rate (DCR), objective response rate (ORR), and adverse event rate were calculated using a random-effects model. Statistical heterogeneity was assessed using the I 2 statistic.

Results

Six studies published between 2024 and 2026, including 80 mCRPC patients treated with 291 cycles of [ 161 Tb]Tb-PSMA RLT, were included. Most patients had pretreated disease and had previously received PSMA-targeted radionuclide therapy. The pooled DCR was 83.9% (95% confidence interval [CI]: 76.0–92.0%) with no significant heterogeneity (I 2 = 0%). The pooled ORR was 50.2% (95% CI: 27.0–74.0%), although significant heterogeneity was observed (I 2 = 81%). Across all studies, 124 adverse events were reported, corresponding to a pooled adverse event rate of 41%, but high grade were only 18.

Conclusion

Current evidence suggests that [ 161 Tb]Tb-PSMA RLT is a promising therapeutic option for patients with mCRPC, demonstrating encouraging disease control and an acceptable safety profile. Nevertheless, defining its precise role requires larger-scale, comparative trials conducted across multiple centers over longer observation periods.

Schlagwörter

Stichwörter der Autor:innen

PSMATb-161meta-analysisnuclear medicineprostate cancerradioligand therapy

Autor:innen und Institutionen

  • Nuclear Medicine, University of Brescia, Brescia, Italy.
  • Nuclear Medicine Department, ASST Spedali Civili di Brescia, Brescia, Italy.
  • Division of Nuclear Medicine, Ente Ospedaliero Cantonale, Bellinzona and Lugano, Switzerland.
  • Faculty of Biomedical Sciences, Università della Svizzera italiana, Lugano, Switzerland.
  • Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland.

Zitieren

APA

Albano, D., Paone, G., & Treglia, G. (2026). Efficacy and safety of [161Tb]Tb-PSMA radioligand therapy in metastatic castration resistant prostate cancer: a systematic review and meta-analysis. Frontiers in Medicine, 13. https://doi.org/10.3389/fmed.2026.1925657

Vancouver

Albano D, Paone G, Treglia G. Efficacy and safety of [161Tb]Tb-PSMA radioligand therapy in metastatic castration resistant prostate cancer: a systematic review and meta-analysis. Frontiers in Medicine. 2026;13. doi:10.3389/fmed.2026.1925657

BibTeX
@article{Albano2026,
  author = {Albano, Domenico and Paone, Gaetano and Treglia, Giorgio},
  title = {Efficacy and safety of [161Tb]Tb-PSMA radioligand therapy in metastatic castration resistant prostate cancer: a systematic review and meta-analysis},
  journal = {Frontiers in Medicine},
  year = {2026},
  volume = {13},
  doi = {10.3389/fmed.2026.1925657}
}
Kostenlos starten →